Abstract
Distribution of Characteristic Mutations in Native Ductal Adenocarcinoma of the Pancreas and Pancreatic Cancer Cell Lines Although oncological treatment of pancreatic adenocarcinoma (PDAC) has improved within the last few years, PDAC continues to have a very low 5- year survival rate. Basic research is needed to improve and develop new therapeutic strategies. Pancreatic tumour cell lines (CLs) are a prerequisite for such basic research. However, the isolation of CLs is challenging. Outgrowth of cells is only achieved in a small proportion of tumour samples, although the reason for this poor growth remains unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
